Seeking Alpha

Idenix soars on huge volume

  • Shares of Idenix Pharmaceuticals (IDIX +32.8%) are on-the-move this morning, trading sharply higher on heavy volume.
  • Although there are no readily apparent catalysts for the move, the company did give an HCV pipeline update Wednesday along with its Q3 report.
  • Summary: Enrollment initiated for IDX21437 Phase 1/2, enrollment complete in HELIX-1 (that's the samatasvir/ simeprevir/ ribavirin GT1b and GT4 trial) with SVR4 data expected in Q4.
  • Also of note, IDIX said its cash "will be sufficient to sustain its operations through December 2014." (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs